Breaking Finance News

Societe Generale upgraded Ipsen S.A. (OTCMKTS:IPSEY) from Hold to Buy in a report released today.

Yesterday Ipsen S.A. (OTCMKTS:IPSEY) traded 2.95% higher at $34.54. The company’s 50-day moving average is $33.01 and its 200-day moving average is $30.32. The last stock close price is up 17.30% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 620 shares of IPSEY traded hands, down from an average trading volume of 925

Societe Generale has upgraded Ipsen S.A. (OTCMKTS:IPSEY) from Hold to Buy in a report released on 9/20/2017.

Recent Performance Chart


Ipsen S.A. has 52 week low of $16.24 and a 52 week high of $35.71 with a PE ratio of 45.01 and has a market capitalization of $0.

Brief Synopsis On Ipsen S.A. (OTCMKTS:IPSEY)

Ipsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Primary Care and Specialty Care. The company offers drugs in urology – oncology, endocrinology, neurology, gastroenterology, cognitive disorders, rheumatology, and cardiovascular areas. Its products include Decapeptyl, a synthetic hormone made of triptorelin and decapeptide analog of gonadotrophin releasing hormone, for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; Hexvix, a photosensitizing agent, for detection and resection of non invasive bladder cancer; and Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors. The company also provides NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum toxin type A complex used to treat cervical dystonia, cerebral palsy, blepharospasms, and hemifacial spasms. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan for the treatment of age-related cognitive disorders. Further, the company provides Nisis and Nisisco, which are antihypertensive agents for treating hypertension; Adenuric for the treatment of gout; and Adrovance for treating post-menopausal osteoporosis. Additionally, it is developing chimeric somastatin and dopamine agonist molecule, BN82451, VSN16R, OPS201, OPS202, MCNA, and LX1032 drugs. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.